We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?
Read MoreHide Full Article
ADMA Biologics, Inc. (ADMA - Free Report) markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company markets Bivigam (to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
ADMA Biologics’ top line currently comprises sales of these three FDA-approved products. The company’s commercial specialty biologics product portfolio is witnessing exponential growth and the momentum is most likely to continue.
Last month, the FDA approved ADMA Biologics’ supplemental biologics license applications (BLAs) for both Asceniv and Bivigam. The latest approval from the regulatory body extended the approved 4-week room temperature (25°C) storage conditions during the first 24 months of shelf life to allow for a 4-week room temperature storage at any point during the entire 36-month approved shelf life for Asceniv and Bivigam.
The FDA nod for the extension of room temperature storage conditions for Asceniv and Bivigam is expected to boost sales of these immunoglobulin products in 2024.
Owing to the strong sales performance of its commercial products in 2023, ADMA Biologics increased its revenue guidance for 2024 and 2025.
The company now expects 2024 and 2025 revenues to be more than $330 million and $380 million, respectively, compared with the previous guidance of $320 million and $370 million, respectively.
ADMA Biologics is also looking to advance the pre-clinical work for its S. pneumonia hyperimmune globulin pipeline program later in 2024. S. pneumonia is the main cause of community-acquired pneumonia in the United States. Per the company, if successfully developed and approved, S. pneumonia hyperimmune globulin could generate peak annual revenues of $300-$500 million.
Given its sound cash position and the promising S. pneumonia hyperimmune globulin program expected to begin this year, investor focus remains on ADMA stock, which has risen 37.6% so far this year against a decrease of 5.7% for the industry.
Image Source: Zacks Investment Research
ADMA Biologics has a Zacks Rank #1 (Strong Buy). In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents. Also, estimates for 2025 earnings per share have improved from 32 cents to 50 cents in the past 60 days.
In the past 60 days, estimates for Cytek Biosciences’ 2024 earnings per share have improved from 2 cents to 8 cents. Year to date, shares of CTKB have declined 26.5%.
CTKB’s earnings beat estimates in one of the trailing four quarters and missed the same on the remaining three occasions, the average negative surprise being 20.84%.
In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have gained 11.5%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.43. Year to date, shares of ANIP have jumped 22.6%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?
ADMA Biologics, Inc. (ADMA - Free Report) markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company markets Bivigam (to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
ADMA Biologics’ top line currently comprises sales of these three FDA-approved products. The company’s commercial specialty biologics product portfolio is witnessing exponential growth and the momentum is most likely to continue.
Last month, the FDA approved ADMA Biologics’ supplemental biologics license applications (BLAs) for both Asceniv and Bivigam. The latest approval from the regulatory body extended the approved 4-week room temperature (25°C) storage conditions during the first 24 months of shelf life to allow for a 4-week room temperature storage at any point during the entire 36-month approved shelf life for Asceniv and Bivigam.
The FDA nod for the extension of room temperature storage conditions for Asceniv and Bivigam is expected to boost sales of these immunoglobulin products in 2024.
Owing to the strong sales performance of its commercial products in 2023, ADMA Biologics increased its revenue guidance for 2024 and 2025.
The company now expects 2024 and 2025 revenues to be more than $330 million and $380 million, respectively, compared with the previous guidance of $320 million and $370 million, respectively.
ADMA Biologics is also looking to advance the pre-clinical work for its S. pneumonia hyperimmune globulin pipeline program later in 2024. S. pneumonia is the main cause of community-acquired pneumonia in the United States. Per the company, if successfully developed and approved, S. pneumonia hyperimmune globulin could generate peak annual revenues of $300-$500 million.
Given its sound cash position and the promising S. pneumonia hyperimmune globulin program expected to begin this year, investor focus remains on ADMA stock, which has risen 37.6% so far this year against a decrease of 5.7% for the industry.
Image Source: Zacks Investment Research
ADMA Biologics has a Zacks Rank #1 (Strong Buy). In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents. Also, estimates for 2025 earnings per share have improved from 32 cents to 50 cents in the past 60 days.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Cytek Biosciences Inc. (CTKB - Free Report) , Ligand Pharmaceuticals Incorporated (LGND - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each sporting a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Cytek Biosciences’ 2024 earnings per share have improved from 2 cents to 8 cents. Year to date, shares of CTKB have declined 26.5%.
CTKB’s earnings beat estimates in one of the trailing four quarters and missed the same on the remaining three occasions, the average negative surprise being 20.84%.
In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have gained 11.5%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.43. Year to date, shares of ANIP have jumped 22.6%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.